HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

High rates of breast conservation for large ductal and lobular invasive carcinomas combining multimodality strategies.

Abstract
The literature reports low rates of breast conservation after neoadjuvant chemotherapy for operable breast cancers not amenable to initial breast-conserving surgery. This study aims to compare the outcome of lobular vs ductal carcinomas after neoadjuvant chemotherapy. Between 1989 and 1999, 750 patients with clinical stage II/IIIA ductal (672) or lobular (78) invasive breast carcinomas were treated at the Institut Curie with primary anthracycline-based polychemotherapy followed by either breast conservation (surgery and/or radiotherapy) or mastectomy. Median follow-up was 10 years. Clinical response to primary chemotherapy was significantly worse for lobular than for ductal carcinomas (47 vs 60%; P=0.04), but only histological grade remained predictive in multivariate analysis. Breast conservation was high for both ductal and lobular carcinomas (65 and 54%; P=0.07), due, in part, to the use of radiotherapy, either exclusive or preoperative, for respectively 26 and 40% of patients. The lobular type had no adverse effect, neither on locoregional control nor on overall survival, even in the group of patients treated with breast conservation.
AuthorsM A Bollet, A Savignoni, J-Y Pierga, M Lae, V Fourchotte, Y M Kirova, R Dendale, F Campana, B Sigal-Zafrani, R Salmon, A Fourquet, A Vincent-Salomon
JournalBritish journal of cancer (Br J Cancer) Vol. 98 Issue 4 Pg. 734-41 (Feb 26 2008) ISSN: 0007-0920 [Print] England
PMID18253121 (Publication Type: Comparative Study, Journal Article)
Topics
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Breast Neoplasms (therapy)
  • Carcinoma, Ductal, Breast (therapy)
  • Carcinoma, Lobular (therapy)
  • Chemotherapy, Adjuvant
  • Female
  • Follow-Up Studies
  • Humans
  • Mastectomy, Segmental
  • Middle Aged
  • Neoadjuvant Therapy
  • Neoplasm Invasiveness
  • Prognosis
  • Radiotherapy, Adjuvant
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: